Epigenomics AG | Mutual Funds

Mutual Funds that own Epigenomics AG

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Squad Capital - Value
500,000
2.08%
150,000
0.42%
12/31/2017
Apus Capital Revalue Fonds
275,000
1.14%
275,000
0.39%
09/30/2017
Amundi Europe Micro Caps
126,848
0.53%
0
0.19%
01/31/2018
C+F Optimum
75,000
0.31%
0
0.12%
06/29/2018
UniSector: BioPharma
59,365
0.25%
-59,051
0.04%
03/31/2018
MOZART One
50,000
0.21%
-201,815
0.14%
12/31/2017
SPDR S&P World (ex-US) ETF
9,284
0.04%
36
0%
09/06/2018
AcomeA Europa
2,700
0.01%
-1,300
0.01%
10/31/2017
AcomeA Globale
1,659
0.01%
659
0.01%
10/31/2017
0
0%
-97,802
0%
06/29/2018

About Epigenomics

View Profile
Address
Geneststraße 5
Berlin Berlin 10829
Germany
Employees -
Website http://www.epigenomics.de
Updated 07/08/2019
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, and Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA. The comapny was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo Gut on April 30, 1997 and is headquartered in Berlin, Germany.